Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEC585 in Idiopathic Pulmonary Fibrosis
NCT05060822Phase 2Active, not recruiting
- Sponsor
- Sunshine Lake Pharma
- Start
- Jun 2021
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of yifenidone in idiopathic pulmonary fibrosis (IPF), sponsored by Sunshine Lake Pharma. Started Jun 2021; status: active, not recruiting.
02
Drugs
yifenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05060822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05060822.